Recent shortages have frustrated patients, proving that logistics are as critical as innovation
In TRIUMPH-1, the pivotal Phase 3 general-obesity trial (2,339 participants), the topline results reported on May 21, 2026 showed average weight loss at 80 weeks of 19.0% on 4 mg, 25.9% on 9 mg, and 28.3% (70.3 lbs) on 12 mg, versus 2.2% on placebo
These generated linkers, with a QED between 0.34 and 0.63, share the same functional groups as the reference linker at both ends, but the chemical structures between these ends differ
Our realworld data show that many patients who stop semaglutide or tirzepatide restart the medication or transition to another obesity treatment, which may explain why they regain less weight than patients in randomized trials, Dr
Carlos E
For brain health, peptides like Selank, Semax, and Dihexa may support cognitive function, ease anxiety, and aid mood by working with your brain's natural repair mechanisms